DeHeng Assisted Healthgen Biotech in Listing on SSE STAR Market

2025-10-28

On October 28, 2025, Wuhan Healthgen Biotechnology Corp. (“Healthgen Biotech”, Stock Code: 688765) was officially listed on the Science and Technology Innovation Board (STAR Market) of the Shanghai Stock Exchange (SSE). It is one of the first batch of newly registered enterprises on the Sci-Tech Growth Tier of the STAR Market and the first company to pass the review following the resumption of the Fifth Set of Listing Standards on the STAR Market. Healthgen Biotech publicly issued over 89.45 million shares at a price of RMB 29.06 per share, raising total gross proceeds of approximately RMB 2.6 billion.

As the issuer’s legal counsel for this IPO, the DeHeng team was led by partner Liu Yan from its Changsha Office, with primary support from partners Wang Xi and Zhu Zhikui from the Wuhan Office. The team worked closely with the issuer and other intermediary institutions, facilitated the successful listing against the backdrop of significant changes in the capital market and regulatory landscape, and earned high praise from the client and other intermediary institutions.